Video
Dr. Hwang on the Evolution of Treatment in Metastatic CSPC
Author(s):
Clara Hwang, MD, discusses the evolution of treatment for men with metastatic castration-sensitive prostate cancer.
Clara Hwang, MD, a medical oncologist with Henry Ford Health System, discusses the evolution of treatment for men with metastatic castration-sensitive prostate cancer (mCSPC).
Historically, the standard of care for men with metastatic prostate cancer was androgen deprivation therapy, says Hwang. Subsequently, docetaxel showed an overall survival (OS) benefit versus standard-of-care therapy in the phase III CHAARTED and STAMPEDE trials.
Additionally, abiraterone acetate (Zytiga) demonstrated an improvement in OS versus standard-of-care therapy in the phase III LATITUDE trial, leading to its approval in 2018 in men with newly diagnosed mCSPC.
In 2019, enzalutamide (Xtandi) and apalutamide (Erleada) were approved for the treatment of patients with newly diagnosed mCSPC based on findings from the phase III ARCHES and TITAN trials, respectively.
